Home | Clinical Care | Research | Training | Division Activities

Education and Training:

M.D., Crimea Medical Institute, Simferopol, Ukraine (1987-93)

Critical Care Medicine Residency, Department of Critical Care and Anesthesiology, Crimea Medical Institute Medical Center, Simferopol, Ukraine (1993-95)

Post-doctoral Research Fellow, Division of Rheumatology and Clinical Immunology, University of Maryland, Baltimore, MD (1995-00)

Internship, York Hospital, York, PA (2000-01)

Hematology/Oncology Fellow, University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA (2003-06)

Andrei Shustov, M.D.
Associate Professor of Medicine, Division of Hematology
University of Washington School of Medicine

Research Associate
Fred Hutchinson Cancer Research Center
Office Address:
Seattle Cancer Care Alliance
Mailbox G3-200
825 Eastlake Ave., East
Seattle, WA 98109-1024

Phone:  (206) 288-6739
Fax:      (206) 288-6473
E-mail:  ashustov@u.washington.edu



CURRENT RESEARCH INTERESTS

Development of novel therapeutic strategies and implementation of targeted biologic agents into treatment paradigms of peripheral T-cell lymphomas and cutaneous T-cell lymphomas



CURRENT CLINICAL INTERESTS

Non-Hodgkin and Hodgkin lymphomas, T-cell lymphomas, cutaneous T-cell lymphomas, and acute lymphocytic leukemia


CLINICAL RESEARCH CONTACT
Lara B. Schiff, MPH
Clinical Research Manager
Phone:  (206) 288-6787
Email:  lschiff1@seattlecca.org

RESEARCH DESCRIPTION

Active Clinical Trials:

A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects with Relapsed or Refractory Hematologic Malignancies (Gilead Sciences, Inc.)

A randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomas (Seattle Genetics, Inc.)

A Phase 1, Dose-Finding Study of Folotyn ® (Pralatrexate Injection) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Patients with Peripheral T-Cell Lymphoma (PTCL) (Spectrum Pharmaceuticals, Inc.)

A Phase 2 study of high dose chemotherapy with autologous stem cell transplant followed by maintenance therapy with romidepsin for the treatment of T-cell Non-Hodgkin Lymphoma (Memorial Sloan Kettering Cancer Center)

A Phase 2, Single-Arm, Open-Label, Multicenter, Study of Folotyn ® (Pralatrexate Injection) in Combination with Oral Leucovorin to Prevent or Reduce Mucositis in Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL) (Spectrum Pharmaceuticals, Inc.)




Active Clinical Trials/Closed to Enrollment:

Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (mogamulizumab) Versus Vorinostat in Subjects with previously Treated Cutaneous T-Cell Lymphoma (Kyowa Hakko Kirin Pharma, Inc.)

A Phase 3, Randoomized, Two-Arm, Open-Label, Multicenter, International Trial of Alisertib (MLN8237) or Investigator's Choice (Selected Single Agent) in Patients with Relapsed or Refractory Peripheral T-Cell Lymphomas (Millennium Pharmaceuticals, Inc.)

An Open-Label, Phase 1/2 Study of Inotuzumab Ozogamicin in Subjects with Relapsed or Refractory CD22-Positive Acute Lymphocytic Leukemia (Pfizer, Inc.)

A Phase 2 Study of SGN-35 in treatment of patients with relapsed or refractory systemic anaplastic large cell lymphooma (ALCL) (Seattle Genetics, Inc.)

A Phase 1 Study of Brentuximab Vedotin Administered Sequentially and Concurrently with multi-Agent Chemotherapy as Front-Line Treatment in Patients with CD30-Positive Mature T-Cell and NK-Cell Neoplasms, Including Systemic Anaplastic Large Cell Lymphoma (Seattle Genetics, Inc.)

A Phase 2 Study of MK-3475 for the treatment of Relapsed/Refractory Mycosis Fungoides/Sézary Syndrome (CITN-Cancer Immunotherapy Trials Network)




Registries:

Prospective collection of data in patients with peripheral T-cell Lymphoma (Peripheral T-cell lymphoma unspecified: Angioimmunoblastic T-cell lymphoma; Extranodal NK/T-cell lymphoma; Enteropathy - type T-cell lymphoma; Hepatosplenic gamma-delta T-cell lymphoma; Subcutaneous panniculitis-like T-cell lymphoma; Anaplastic large-cell lymphoma, T/null cell, primary systemic type.) (international T-cell Non-Hodgkin's Lymphoma Study Group)

Prospective, Longitudinal, Multinational Registry of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma (Allos Therapeutics, Inc.)

A Retrospective Evaluation of Peripheral T-cell Lymphoma Patients (Yolanda Willis Research Fund, University of Washington)


SELECTED PUBLICATIONS

1. Shustov AR, Gooley TA, Sandmaier BM, Shizuru J, Sorror ML, Sahebi F, McSweeney P, Niederwieser D, Bruno B, Storb R, Maloney DG.; Allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas. Br. J. Haematol. 2010;150(2):170-178

2. Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Marchandren R, Fanale M, Connors JM, Yang Y, Sievers EL, Kennedy DA, Shustov A; Brentuximab Vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma: results of a phase II study. J. Clin. Oncol. 2012;30(18):2190-6

3. Fanale MA, Horwitz SM, Forero-Torres A, Bartlett NL, Advani RH, Pro B, Chen RW, Davies A, Illidge T, Huebner D, Kennedy DA, Shustov AR; Brentuximab Vedotin in the Frontline Treatment of Patients with CD30+ Peripheral T-cell Lymphomas: Results of a Phase 1 Study. J. Clin. Oncol. 2014;32(28):3137-43

4. OA O'Connor, S Horwitz, T Masszi, A Van Hoof, P Brown, J Doorduijn, G Hess, W Jurczak, P Knoblauch, S Chawla, G Bhat, MR Choi, J Walewski, K Savage, F Foss, LF Allen, AR Shustov; Belinostat in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma. J. Clin. Oncol. 2015 Aug 10;35(23):2492-9

5. Scott V. Adams, Polly A. Newcomb, and Andrei R. Shustov; Racial Patterns of Peripheral T-cell Lymphomas incidence and Survival in The United States. J. Clin. Oncol. 2016 Jan 25: pii: JCO635540. [Epub ahead of print]